Home » Awareness » The Invisible Neuroendocrine Tumor Patient Population 

The Invisible Neuroendocrine Tumor Patient Population 


 

 

I found some of the quotes from the recent NET SEER Database study (Dasari et al) very interesting.  The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program is a comprehensive source of population-based information initiated in 1973 that is updated annually. Although the study is US-based, it did represent the largest study of Neuroendocrine Tumors (NETs) ever recorded. Other national declarations of incidence and prevalence of NETs seem to bear these statistics out.

I covered the increasing incidence and prevalence extensively in my post “Neuroendocrine Tumors – not as rare as you think“.  I looked at USA and beyond. Those who are regular readers of my articles will already know I’ve been ‘banging on’ about this for a few years. Other organisations and individuals (including NET specialists) are now indicating these tumors are not rare, some vindication for my aforementioned ‘banging on’.

SEER 2012 Underestimated

There are two further quotes which I’d like to focus on in this article:

1. From the NET SEER Database study published 2017:

…… many cases of NETs may not have been reported to cancer registries unless considered malignant…… it is likely that we have underestimated their true incidence and prevalence

2. From Dana Farber (Kulke, Chan):

“Estimated more than 200,000 undiagnosed cases in the US”

But what do these quotes actually mean?  Here’s my take!

Underestimating the true incidence and prevalence of NETs

I studied the latest SEER NET study, formally titled “Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States” (authored by Arvind Dasari, MD, MS; Chan Shen, PhD; Daniel Halperin, MD; et al). From this document, I can see the authors were aware of the well-known faults in cancer registries worldwide and the effect this has on the true incidence and prevalence of Neuroendocrine Cancer.  These issues, which are a worldwide problem, include the incorrect registration of Neuroendocrine Cancer as other types based on the anatomical location of the primary tumor.  At this point, you may wish to check out my post “The Human Anatomy of Neuroendocrine Cancer” which provides some real life examples of the confusion between primary Neuroendocrine location and other cancers. That said, things are definitely improving because the latest SEER data shows a marked increase in the incidence of High Grade Neuroendocrine Carcinomas (NEC), an area where this issue is prevalent. A similar increase in NEC was also illustrated in the UK’s figures from Public Health England (PHE) in 2016 (click here) indicating that cancer registries are getting better and not before time (although it has to be said this only came about due to a major intervention by NET Patient Foundation and others).

But there’s another issue impacting whether a diagnosis is actually entered on a cancer registry or not.  Unfortunately, there are members of the medical community who still see well differentiated NETs as benign tumors, ‘not a proper cancer’ and some of them are still living in last century (‘Carcinoid World’).  You can occasionally be excused for being out of date but being 7 years (plus) out of date is unacceptable.  The WHO 2010 classification for NETs was based on the concept that all NETs have malignant potential.  Here’s a quote from the UKINETS Guidelines in 2011 (Ramage, Caplin, Meyer, Grossman, et al).

Tumours should be classified according to the WHO 2010 classification (Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System. Lyon: IARC, 2010). This classification is fundamentally different from the WHO 2000 classification scheme, as it no longer combines stage related information with the two-tiered system of well and poorly differentiated NETs. The WHO 2010 classification is based on the concept that all NETs have malignant potential, and has therefore abandoned the division into benign and malignant NETs and tumours of uncertain malignant potential.

The guidance in WHO 2017 reinforces this statement.

The undiagnosed NET patient population

From above, you can see why the incidence (and therefore the prevalence) of our disease has almost definitely been underestimated.  However, that’s not the end of my story……..

A number of statements are clear about Neuroendocrine Tumors:

  • Low/Intermediate grade well differentiated tumors are known to have been growing slowly over a number of years before discovery or accurate diagnosis occurs,
  • They can be difficult to diagnose,
  • They are not that well-known amongst the general medical population,
  • Many people are initially misdiagnosed with another condition, with some this will result in late presentation with metastatic disease.

It’s worth pointing out that one of the conclusions made by the recent SEER NET study is that the increase in incidence and prevalence can be attributed to a number of factors including earlier diagnosis.  This is of course excellent news.  Also worth noting that another conclusion of the study is that we are all living longer, reflecting improvements in therapies.  This is also great news and is a factor in increased prevalence figures.

Summary

I suspect there’s an invisible patient population for many conditions but the slow-growing and relatively quiet nature of Neuroendocrine Cancer means there could be a significant undiagnosed burden walking around, looking for a diagnosis, putting up with symptoms and being treated for other conditions. I see people on forums looking for clues, social media can sometimes be helpful here. That said, I do get the feeling some do not have NETs, regardless of the symptoms they associate with the disease, but I guess many of them will go on to be formally diagnosed with something. I’m contacted by many ‘undiagnosed’ people on my own blog and supporting Facebook sites (mostly privately) and I can tell you that’s a tough gig.  I only hope I’ve given them some useful ideas about where to look or what to ask/suggest.

Clearly more awareness is required to catch more people earlier and from the latest SEER NET study, it appears this is starting to work.  I feel earlier diagnosis is partly due to increased awareness, particularly in the medical world. I would also suggest that it has improved in the general population to the explosion of social media information dissemination. It’s also accurate to suggest that improvements in diagnostic capabilities is also playing its part in pushing up incidence rates, just as improved therapies have pushed up prevalence rates, something emphasised by Dasari (et al) in the recent SEER Data study.

The issues caused by inefficient registries together with ‘the undiagnosed’, combine to suggest there is a large invisible NET patient population out there ……. we just need to find them!

Thanks for reading

Ronny

Hey, I’m also active on Facebook.  Like my page for even more news.

Disclaimer

My Diagnosis and Treatment History

Most Popular Posts

Sign up for my twitter newsletter

Check out my Podcast (click and press play)

Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!

community_titled_transparent_2013-10-22

Please Share this post


12 Comments

  1. edebock says:

    My NETs specialist, who is also a research scientist, believes that though the increase in incidence is partially due to earlier diagnosis, NETs is actually on the increase, but it’s not known why.

    https://polldaddy.com/js/rating/rating.js

    Liked by 1 person

  2. Deanna Vickery, Mrs says:

    As usual a very interesting article which makes me think that the most important factor to finding these invisible patients is intensive training for the first-contact points ie our GPs.
    Thankyou Ronny.

    Liked by 1 person

    • Ronny Allan says:

      Thanks Deanna. I’m personally not so sure that GP’s should be the main target of awareness. It is more likely that a patient will be actually diagnosed at secondary care and so gastroenterologists, oncologists, and even pathologists should be a target. Many people are referred to secondary care for “something” based on the presentational symptoms and the action of secondary care is critical. Many people are sent back to primary care from secondary care nothing found. The problem for GPs is that NETs is one of 200 cancers and one of 10,000 conditions and it’s impossible for GPs to be given “intensive training” in every single one of them. Their gut instinct, hopefully honed by 10 years of training, normally works for most. That’s not to say we should not include them in our awareness activities but the ‘NETs primer’ we send them is there alongside the ‘a’ disease primer, the ‘b’ disease primer, the ‘c’ disease primer and so on. Most of these primers will unfortunately and understandably become ‘shelfware’. Just my opinion though.

      Like

  3. Jeff Drifmeyer says:

    ‘a large invisible NET patient population out there ……. we just need to find them’
    thanks for pointing this out. But, begs the question…what can be done about it? i.e. How do we, in fact, “find them?”
    Any thought of mounting a case finding campaign? Excellent care is available its just hard then it should be to get to, as you point out.
    ..perhaps in coordination with world NET day in Nov?
    without such a concerted effort, lives among the estimated 200K will be lost due to misdiagnosis, and inappropriate treatment. We can do better
    thnx
    Jeff D


    https://polldaddy.com/js/rating/rating.js

    Liked by 1 person

    • Ronny Allan says:

      Well we are finding them, as you will have read, the increase in incidence is a direct result of earlier diagnosos. Ergo, the figure some years ago was very probably way above 200,000. No-one can deny that my blog is not spreading awareness, so I guess I’m doing my bit. Remember, I’m just a wee Scottish patient. However, I think the community as a whole could be more effective if it dropped the ineffectual and crazy fascination with black and white striped animals. We could certainly do better than that.

      Like

    • Ronny Allan says:

      p.s. I didn’t initially point it out, Dana Farber NET specialists did! I’m just quoting it.

      Like

  4. grantsviews says:

    ************** SUPERB *****************
    Thanks Ronny!


    https://polldaddy.com/js/rating/rating.js

    Liked by 1 person

Thanks for the comment, make sure you have ticked the box to receive notifications of responses

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 10,228 other followers

Follow Ronny Allan – Living with Neuroendocrine Cancer on WordPress.com

Blog Stats

  • 423,192 hits

Recent Posts

%d bloggers like this: